Home > Boards > US OTC > Medical - Drugs >

Kyowa Hakko Kirin Co., Ltd. (KYKOF)

Add KYKOF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/10/2015 12:59:40 PM - Followers: 0 - Board type: Free - Posts Today: 0

Kyowa Hakko Kirin Co., Ltd. 1-6-1, Ohtemachi Chiyoda-ku Tokyo, 100-8185 Japan Phone: 81 3 3282 0007 Fax: 81 3 3284 1968 Website: http://www.kyowa-kirin.co.jp Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KYKOF News: Kyowa Kirin Co., Ltd. GAAP EPS of ¥97.39, revenue of ¥352.25B 02/07/2022 12:53:04 PM
KYKOF News: Cumberland Pharmaceuticals acquires Sancuso from Kyowa Kirin North America 01/04/2022 04:45:24 AM
KYKOF News: Kyowa Kirin reports Q2 results 08/06/2021 09:21:36 AM
KYKOF News: Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6% 03/29/2021 07:14:52 AM
KYKOF News: Twist Bioscience and Kyowa Kirin team up for GPCR antibody discovery 03/25/2021 12:16:35 PM
#1   $KYKOF recent news/filings stocktrademan 06/10/15 12:59:40 PM
Consent Preferences